Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Breastfeeding after MMR shot: is it safe for baby?

NCT ID NCT02325310

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether the measles vaccine virus can be found in the breast milk of new mothers who received the MMR vaccine shortly after giving birth. Fourteen breastfeeding women with no immunity to measles or rubella provided milk samples over two weeks. The goal was to understand if the vaccine could affect their babies, helping doctors give better safety advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

14 people

The number who actually took part.

Started

Feb 2015

Finished

Nov 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 36 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Women: * Pregnant woman * Age ≥ 18 years * Planning to breastfeed her infant (mixed feeding is allowed) * Having a negative serology for rubella during pregnancy * Negative serology for measles based on the result from local laboratory * Affiliated to a social security regimen Infants: * Informed consent form signed by the person(s) holding parental authority. * Term newborn (≥36LMP) Exclusion Criteria: Women: * Woman having a multiple pregnancy * Woman planning to get pregnant in the month following the 2nd vaccination * Woman with known or suspected HIV infection * Woman with known or suspected immunodeficiency * Woman with family history of hereditary immune deficiency * Woman not mastering enough the reading / understanding of the French language to be able to consent to participate to the study * Woman incapable to follow the procedures of the study and to respect study visits for the whole period of the study. * Woman with contraindication for MMR vaccination: * Scarce hereditary problems of fructose intolerance * Woman with history of hypersensitivity to the active substances or to any of the excipients of the vaccine * Administration of human gammaglobulins in the past 3 to 11 months depending on the dose of human globulins administered (except for Rhophylac®) * Acute severe febrile illness within 7 days prior to injection * Woman under systemic corticosteroids (prednisone, or equivalent ≥10 mg/day) within the previous 15 days or planning to use corticosteroids (i.e. prednisone, or equivalent ≥10 mg/day) during the 15 days following vaccination * Woman under immunosuppressive therapy within the previous 3 months before vaccination or planning to use immunosuppressive therapy during the 15 days following vaccination Woman participating in any clinical trial with another investigational product 28 days prior to visit V0 or intent to participate in another clinical study with another investigational product at any time during the conduct of this study * Any other reason which, according to the investigator, may interfere with the evaluation of the study objectives * Woman with documented history of measles vaccination (1 or 2 doses) and/or history of documented measles Infants: * Blood draw is contraindicated or cannot be performed * Infant with family history of hereditary immune deficiency * Infant with suspected or confirmed immunodeficiency * Any other reason which, according to the investigator, may interfere with the evaluation of the study objectives

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Measles are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cochin Port Royal Hospital - Centre d'Investigation Clinique Cochin-Pasteur

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.